Blood test guides extra treatment to fight lymphoma in seniors
NCT ID NCT06828991
Summary
This study is testing a personalized approach to improve outcomes for older adults with a type of blood cancer called DLBCL. After initial chemotherapy, a blood test checks for tiny traces of leftover cancer. If found, patients receive an additional targeted antibody drug called mosunetuzumab. The goal is to clear these cancer traces from the blood, aiming for better long-term disease control with careful monitoring of safety and how patients feel.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wilmot Cancer Institute
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.